CoPay Savings Program

Eligible, commercially insured patients with coverage for XHANCE pay as little as $0 using the XHANCE savings card*

Get Savings Card

NOTICE OF RESTRICTION FOR VERMONT HEALTHCARE PROVIDERS

If you are a healthcare professional licensed in Vermont, or a licensed healthcare professional who regularly practices in Vermont, Optinose corporate policy and the terms of this program prohibit you from downloading, printing, or accepting the savings card.

See terms and conditionsSee terms and conditions.

Be sure to download the XHANCE savings card to receive available savings for your patients.

*

These offers are not valid for use by cash-paying patients or patients enrolled in Medicare, Medicaid, and TRICARE or other federal or state programs. Offers are subject to quantity limitations. Maximum benefits per fill apply. Patient cost share may impact benefits and eligibility. Optinose^® reserves the right to rescind, revoke, or amend this offer without notice. Click hereClick here for additional terms and conditions.

ACCESS TO XHANCE

Use the downloadable assets below to learn more about the Patient Support Program, and advocate on behalf of your patients that are seeking access to treatment with XHANCE.

Patient Support Program Flashcard

Access a snapshot of the services provided by the Patient Support Program.

Download Flashcard

Patient Support Program Prescription Form

Fill out the Patient Support Program Prescription Form for your patients seeking additional XHANCE support.

Letter of Appeal

Appeal on behalf of patients who have been seeking coverage of treatment with XHANCE.

Download Letter

Letter of Medical Necessity

Submit this Letter of Medical Necessity to advocate on behalf of patients seeking coverage of treatment with XHANCE.

Download Letter

+

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.